ESMO 2026: Top 10 NSCLC and SCLC presentations

Congress coverage by Medthority

Last updated: 20th Oct 2026

Published: 20th Oct 2026

What are the key lung cancer presentations to look out for at ESMO 2026?

Our expert team have selected 10 oral presentations covering small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC) to look out for at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place on October 23–27 in Madrid, Spain.

Abstract	Title	Presenter	Date	Time (CEST/CET)	Specialty
LBA3	Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial	Jacob Sands	Saturday, October 24, 2026	17:18	SCLC
2613O	Primary results of SARON: a randomised-controlled trial of consolidation radiotherapy for synchronous oligometastatic non-small cell lung cancer	Fiona McDonald	Sunday, October 25, 2026	10:15	NSCLC
2614O	Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020)	Chantal Decroisette	Sunday, October 25, 2026	10:25	NSCLC
LBA66	Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study	Caicun Zhou	Sunday, October 25, 2026	10:53	NSCLC
LBA67	Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study	Wen Feng Fang	Sunday, October 25, 2026	11:03	NSCLC
LBA68	Phase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in previously treated nonsquamous non-small cell lung cancer (NSCLC)	Solange Peters	Sunday, October 25, 2026	11:13	NSCLC
LBA5	Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC	Ferdinandos Skoulidis	Sunday, October 25, 2026	16:30	NSCLC
LBA6	Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results	Shun Lu	Sunday, October 25, 2026	16:54	NSCLC
3808O	Tarlatamab in Previously Treated SCLC: Extended Follow-up of Overall Survival from the Phase 3 DeLLphi-304 Trial	Charles M. Rudin	Monday, October 26, 2026	14:45	SCLC
3809O	Randomized trial of serplulimab or atezolizumab plus chemotherapy in USA patients with extensive-stage small cell lung cancer (ASTRIDE)	David R. Gandara	Monday, October 26, 2026	14:55	SCLC